ARS Pharmaceuticals (SPRY) News Today $12.86 -0.58 (-4.32%) Closing price 04:00 PM EasternExtended Trading$12.98 +0.12 (+0.93%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRY Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period ARS Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 28 at 8:00 AM | globenewswire.comVanguard Group Inc. Has $43.88 Million Holdings in ARS Pharmaceuticals, Inc. $SPRYAugust 28 at 3:12 AM | marketbeat.comARS Pharmaceuticals Inc. (SPRY) Stock Price Today - WSJAugust 24, 2025 | wsj.comARS Pharmaceuticals (NASDAQ:SPRY) CFO Sells 12,500 SharesAugust 23, 2025 | insidertrades.comARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 2.3% Following Insider SellingAugust 23, 2025 | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Insider Sells $173,186.32 in StockAugust 22, 2025 | insidertrades.comAberdeen Group plc Takes $12.61 Million Position in ARS Pharmaceuticals, Inc. $SPRYAugust 21, 2025 | marketbeat.comEquities Analysts Issue Forecasts for SPRY FY2025 EarningsAugust 19, 2025 | marketbeat.comEquities Analysts Offer Predictions for SPRY FY2025 EarningsAugust 19, 2025 | americanbankingnews.comLeerink Partnrs Issues Negative Forecast for SPRY EarningsAugust 19, 2025 | marketbeat.comEquities Analysts Offer Predictions for SPRY Q3 EarningsAugust 19, 2025 | marketbeat.comWilliam Blair Issues Optimistic Forecast for SPRY EarningsAugust 19, 2025 | americanbankingnews.comLeerink Partnrs Issues Pessimistic Outlook for SPRY EarningsAugust 19, 2025 | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPSAugust 15, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | msn.comARS Pharmaceuticals Inc (SPRY) Q2 2025 Earnings Report Preview: What To Look ForAugust 14, 2025 | finance.yahoo.comARS Pharmaceuticals Reports Strong Growth for neffyAugust 14, 2025 | msn.comARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)August 13, 2025 | globenewswire.comEarnings Outlook For ARS PharmaceuticalsAugust 12, 2025 | benzinga.comARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 6.3% - Should You Sell?August 12, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Holdings Raised by Levin Capital Strategies L.P.August 6, 2025 | marketbeat.comXTX Topco Ltd Raises Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)August 6, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Buy" by BrokeragesAugust 5, 2025 | marketbeat.comHere's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price StrengthAugust 4, 2025 | msn.comARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial ResultsAugust 4, 2025 | globenewswire.com14,780 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Acquired by Foster & Motley Inc.August 3, 2025 | marketbeat.comARS Pharmaceuticals (SPRY) Expected to Announce Quarterly Earnings on TuesdayJuly 30, 2025 | marketbeat.comSchulhoff & Co. Inc. Purchases Shares of 40,500 ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)July 28, 2025 | marketbeat.comKnights of Columbus Asset Advisors LLC Invests $543,000 in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)July 27, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Position Lowered by Royce & Associates LPJuly 27, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Downgraded to Sell Rating by Wall Street ZenJuly 26, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Purchased by Legato Capital Management LLCJuly 24, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by FAS Wealth Partners Inc.July 19, 2025 | marketbeat.comEURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)July 18, 2025 | globenewswire.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of "Buy" by BrokeragesJuly 11, 2025 | marketbeat.comARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle EpinephrineJuly 10, 2025 | seekingalpha.comARS Pharmaceuticals: 'Betting On The Come'July 9, 2025 | seekingalpha.comARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 4.6% - Should You Buy?July 7, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Raises Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)July 6, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $254,850.00 in StockJuly 4, 2025 | insidertrades.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 15,000 Shares of StockJuly 3, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Major Shareholder James E. Flynn Sells 740,149 SharesJuly 2, 2025 | insidertrades.comJames E. Flynn Sells 740,149 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockJuly 1, 2025 | marketbeat.comPeregrine Capital Management LLC Boosts Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)July 1, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 5% - Here's What HappenedJune 30, 2025 | marketbeat.comLisanti Capital Growth LLC Buys New Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)June 29, 2025 | marketbeat.com55,714 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Purchased by Matisse CapitalJune 28, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Upgraded at Wall Street ZenJune 28, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Sets New 12-Month High - Still a Buy?June 27, 2025 | marketbeat.com Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPRY Media Mentions By Week SPRY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRY News Sentiment▼0.191.03▲Average Medical News Sentiment SPRY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRY Articles This Week▼95▲SPRY Articles Average Week Get the Latest News and Ratings for SPRY and Related Stocks Enter your email address to receive the latest news and analysts' ratings for ARS Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AXSM News Today NUVL News Today ABVX News Today CRSP News Today MRUS News Today VKTX News Today CYTK News Today AAPG News Today TGTX News Today KRYS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRY) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access